- Home
- ANL vs VTGN Comparison
ANL vs VTGN Comparison
Compare ANL & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANL
- VTGN
- Stock Information
- Founded
- ANL 2004
- VTGN 1998
- Country
- ANL Cayman Islands
- VTGN United States
- Employees
- ANL N/A
- VTGN N/A
- Industry
- ANL
- VTGN Biotechnology: Pharmaceutical Preparations
- Sector
- ANL
- VTGN Health Care
- Exchange
- ANL Nasdaq
- VTGN Nasdaq
- Market Cap
- ANL 72.7M
- VTGN 82.0M
- IPO Year
- ANL 2023
- VTGN N/A
- Fundamental
- Price
- ANL $1.95
- VTGN $3.06
- Analyst Decision
- ANL Strong Buy
- VTGN Strong Buy
- Analyst Count
- ANL 2
- VTGN 2
- Target Price
- ANL $9.00
- VTGN $13.50
- AVG Volume (30 Days)
- ANL 7.5K
- VTGN 161.4K
- Earning Date
- ANL 08-08-2024
- VTGN 11-07-2024
- Dividend Yield
- ANL N/A
- VTGN N/A
- EPS Growth
- ANL N/A
- VTGN N/A
- EPS
- ANL N/A
- VTGN N/A
- Revenue
- ANL $5,000,000.00
- VTGN $971,000.00
- Revenue This Year
- ANL N/A
- VTGN N/A
- Revenue Next Year
- ANL N/A
- VTGN N/A
- P/E Ratio
- ANL N/A
- VTGN N/A
- Revenue Growth
- ANL N/A
- VTGN N/A
- 52 Week Low
- ANL $1.85
- VTGN $2.45
- 52 Week High
- ANL $17.48
- VTGN $5.86
- Technical
- Relative Strength Index (RSI)
- ANL 40.95
- VTGN 49.51
- Support Level
- ANL $1.88
- VTGN $2.87
- Resistance Level
- ANL $2.10
- VTGN $3.09
- Average True Range (ATR)
- ANL 0.12
- VTGN 0.15
- MACD
- ANL 0.03
- VTGN 0.02
- Stochastic Oscillator
- ANL 38.46
- VTGN 79.41
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.